EcoDrugPlus


Trade Names	DOTAREM
Synonyms	Dotarem Gadolinium-dota meglumine Gadoterate meglumine Gd-dota meglumine Magnescope Meglumine gadoterate P 449 P-449 P449
Status
Molecule Category	UNKNOWN
UNII	L0ND3981AG

Trade Names

DOTAREM

Synonyms

Dotarem

Gadolinium-dota meglumine

Gadoterate meglumine

Gd-dota meglumine

Magnescope

Meglumine gadoterate

P 449

P-449

P449

Status

Molecule Category

UNKNOWN

UNII

L0ND3981AG


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Property Name	Value
Molecular Formula	C23H42GdN5O13
Molecular Weight	753.86
AlogP	None
Hydrogen Bond Acceptor	None
Hydrogen Bond Donor	None
Number of Rotational Bond	None
Polar Surface Area	None
Molecular species	None
Aromatic Rings	None
Heavy Atoms	None

Property Name

Value

Molecular Formula

C23H42GdN5O13

Molecular Weight

753.86

AlogP

None

Hydrogen Bond Acceptor

None

Hydrogen Bond Donor

None

Number of Rotational Bond

None

Polar Surface Area

None

Molecular species

None

Aromatic Rings

None

Heavy Atoms

None

Mechanism of Action	Action	Reference
Diagnostic agent	None	DailyMed

Mechanism of Action

Action

Reference

Diagnostic agent

None

DailyMed

Resources	Reference
ChEMBL	CHEMBL2219415
FDA SRS	L0ND3981AG
PubChem	6918037

Resources

Reference

ChEMBL

CHEMBL2219415

FDA SRS

L0ND3981AG

PubChem

6918037


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

GADOTERATE MEGLUMINE

Physicochemical Descriptors

Bioactivity

Cross References